Diamyd Medical’s CEO purchases shares in the Company
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that CEO Ulf Hannelius has purchased 20,000 Series B shares in Diamyd Medical.“Diamyd Medical is in an exciting phase and it is both an obvious move and gratifying for me to also become a shareholder in the company,” says Ulf Hannelius, CEO of Diamyd Medical. About Diamyd MedicalDiamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology. Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based